Allovir Inc (KLRS) Stock Forecast & Price Target

Kalaris Therapeutics is supported by a lead asset, TH103, that is rationally engineered for stronger VEGF inhibition and retinal retention, which directly targets the central limitation of current wet AMD therapy: short durability and frequent injections. Early Phase Ia data are encouraging, with about a 10-letter BCVA gain at one month, roughly 129 µm CST reduction, near-complete fluid resolution, and 31% of patients needing no retreatment through six months, while manufacturing refinements appear to have addressed the earlier inflammation signal. The company also addresses a large commercial opportunity in a $15B+ wet AMD market, with conservative estimates calling for $1.6B of peak global sales by 2040 and additional upside from DME and RVO expansion.

Kalaris Therapeutics is a single-asset, clinical-stage company whose future depends almost entirely on TH103, leaving it highly exposed if the program fails to show durable efficacy, safety, or regulatory success. Despite a large wet AMD market, the company must compete against entrenched anti-VEGF leaders and biosimilars, while also proving that TH103 can overcome the real-world problems of frequent injections, persistent retinal fluid, and limited differentiation that have constrained prior therapies. Financially, Kalaris ended 1Q26 with $104.9M in cash, expected to fund operations into 4Q27, but continued development, commercialization buildout, and likely future dilution create substantial financing risk before any revenue can be realized.